References

Prevalence of hidradenitis Suppurativa

10.1001/jamadermatol.2025.2373 · 2025 · External reference

Hidradenitis suppurativa

10.1016/s0140-6736(24)02475-9 · 2025 · External reference

Genetic susceptibility to hidradenitis Suppurativa and predisposition to Cardiometabolic disease

10.1001/jamadermatol.2024.3779 · 2025 · External reference

10.1001/jamadermatol.2015.6264

10.1001/jamadermatol.2015.6264 · External reference

Risk factors for cardiovascular disease in patients with hidradenitis suppurativa

10.1111/jdv.14225 · 2017 · External reference

10.1001/jamadermatol.2014.691

10.1001/jamadermatol.2014.691 · External reference

10.1111/jdv.20472

10.1111/jdv.20472 · External reference

The influence of body weight on the prevalence and severity of hidradenitis Suppurativa

10.2340/00015555-1800 · 2014 · External reference

A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide

10.1016/j.jdcr.2024.02.023 · 2024 · External reference

The treatment of hidradenitis suppurativa with the glucagon‐like peptide‐1 agonist liraglutide

10.1111/bjd.15233 · 2017 · External reference

Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa

10.1016/j.medcli.2023.11.007 · 2024 · External reference

Semaglutide use for decreasing hidradenitis suppurativa resource utilization: a retrospective cohort study utilizing TriNetX

10.1016/j.jaad.2024.11.039 · 2025 · External reference

Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life

10.1093/bjd/ljae216 · 2024 · External reference

The Danish National Patient Registry: a review of content, data quality, and research potential

10.2147/clep.s91125 · 2015 · External reference

10.1093/ije/dyw213

10.1093/ije/dyw213 · External reference

10.1002/jvc2.70231

10.1002/jvc2.70231 · External reference

10.1136/bmjopen‐2018‐028116

10.1136/bmjopen‐2018‐028116 · External reference

Cardiometabolic risk factors and cardiovascular risk in hidradenitis Suppurativa

10.1001/jamadermatol.2025.2989 · 2025 · External reference

Hidradenitis suppurativa should be recognized as a weight‐related comorbidity in National Institute for health and care guidelines on managing obesity

10.1093/ced/llad109 · 2023 · External reference

10.1080/09546634.2019.1708853

10.1080/09546634.2019.1708853 · External reference

10.1080/09546634.2020.1826392

10.1080/09546634.2020.1826392 · External reference

10.1111/jdv.20694

10.1111/jdv.20694 · External reference

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP‐1 receptor agonists: a retrospective cohort study

10.1016/j.jdin.2025.07.003 · 2025 · External reference

Pain in hidradenitis Suppurativa: a cross‐sectional study of 1,795 patients

2020 · External reference

The impact of GLP‐1 receptor agonists on clinical outcomes and healthcare utilization in hidradenitis suppurativa patients: a retrospective cohort study using TriNetX

10.1016/j.jaad.2025.11.017 · 2026 · External reference

Glucagon‐like Peptide‐1 receptor agonists reduce surgeries and hospitalizations in hidradenitis Suppurativa: a multicenter TriNetX cohort study

10.36849/jdd.8926 · 2025 · External reference

Patient‐reported outcomes of glucagon‐like peptide‐1 agonists on hidradenitis suppurativa severity

10.1016/j.jdin.2025.05.004 · 2025 · External reference